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Introduction: Locally advanced stages of invasive cervical cancer (ICC) are associated with poor outcomes; factors influencing
survival include increased tumour volume. In resource-constrained settings access to diagnostic imaging with CT and MRI is
limited. Alternative methods of establishing tumour volume can be defined with use of the planning target volume (PTV)
delineated prior to radiotherapy. The aim of this study is to determine whether increased PTV size impacted on overall
survival in a cohort of cervical cancer patients with Stage IIB/IIIB disease who completed radical radiotherapy.
Materials and methods: A retrospective analysis was undertaken of patients with histologically confirmed Stage IIB/IIIB ICC
treated with radical radiotherapy. Exclusion criteria included patients who did not complete prescribed radiotherapy and
brachytherapy. Demographic and treatment details were collected. Planning target volumes were retrieved. Kaplan–Meier
analysis was used to calculate the overall survival rate. A multivariate Cox proportional hazard model was derived to assess
associations with all-cause mortality.
Results: A total of 71 patients met the inclusion/exclusion criteria. The median PTV was 653 cc. On univariate analysis factors
significantly associated with a lower overall survival included HIV positivity and the presence of hydronephrosis. Increased
PTV size paradoxically showed a trend to improved overall survival. On multivariant analysis HIV status, advanced stage,
hydronephrosis and a smaller PTV were significantly related to higher all-cause mortality.
Conclusion: It is concluded that, when using planning target volumes, the hypothesis that larger volumes impact on overall
survival was disproved. A larger cohort and more accurate methods of determining tumour volume, including PET/CT, will
be considered in future prospective studies.
Keywords cervix carcinoma, tumour volume, radiotherapy, survival
Introduction
The National Cancer Registry of 2010 lists invasive cervical
cancer (ICC) as the second most common malignancy among
females in South Africa.1 The developing world carries the hea-
viest burden with 80% of patients residing in these regions.
Initial diagnosis is frequently at an advanced stage.
It has long been recognised that more advanced stages of
cancer are associated with poor outcomes.2–5 However, the
FIGO staging system is limited in its prognostic and predictive
value as known pathological factors, such as histological
subtype and tumour size, are not included for all stages.
Current staging additionally does not allow for inclusion of
cross-sectional imaging findings.6 Limitations of clinical
staging are especially apparent in advanced disease. A more
precise and objective method, such as CT or MRI, is preferable.7
It was acknowledged that tumour volume influenced prognosis in
less advanced cervical cancer (IB–IIA) and therefore the FIGO
system was updated to designate differences based on volume
greater than or less than 4 cm.8 It is reasonable to extrapolate
that the same might hold true for a more detailed subdivision of
locally advanced disease (Stage IIB and IIIB). Unfortunately there
is a lack of consistent access to diagnostic CT, MRI and PET-CT in
resource-limited settings. In centres with planning CT scans and
tumourdelineationsoftware there is thepotential touse theclinical
tumour volume delineated as a surrogate marker for tumour size.
This retrospective review aimed to investigate the effect of
the size of planning tumour volume on five-year overall
survival for locally advanced cervical cancers (FIGO Stages
IIB and IIIB).
Materials and methods
Study design and population
A retrospective analysis of all patients with histologically con-
firmed Stage IIB and IIIB ICC treated with radical radiotherapy
between January 2011 and December 2011 at Tygerberg Aca-
demic Hospital in the Western Cape, South Africa was per-
formed. Patient hospital numbers were retrieved from the
clinic registry.
Exclusion criteria included patients who did not complete the
full course of prescribed radiotherapy and brachytherapy.
Clinical and demographic information was obtained from insti-
tutional databases. Data collected included patient age,
human immunodeficiency virus (HIV) status, histology, stage of
disease, presence of lymph nodes or hydronephrosis. The treat-
ment regimen including external beam radiotherapy (EBRT) and
high-dose-rate brachytherapy, dose and fractionation, total
number of chemotherapy cycles administered, and overall treat-
ment time was documented. Radiotherapy planning target
volume (PTV) was retrieved from the divisional planning
system. Size was determined by a computer algorithm calculat-
ing the cubic centimetre (cc) volume. The planning system used
in this retrospective review was unable to retrieve CTV (clinical
target volume) for all patients and therefore necessitated the
use of PTV. The CTV included the primary disease, cervix,
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uterus and parametria. PTV included the CTV with a 1.5 cm
margin in the anterior-posterior plane and 1 cm in all other
directions.
Vital status or last follow-up date was retrieved from hospital
records and national death registry data.
Treatment
Disease stage was evaluated and confirmed at the weekly multi-
disciplinary team meeting. Staging was performed according to
the FIGO classification and included physical examination,
imaging (abdominal ultrasound, chest X-ray) and cystoscopy.
A contrasted planning CT scan was performed for all patients
undergoing radiotherapy. The field of view commenced at the
bottom of the T12 vertebra to mid-femur with a 5 mm slice
thickness. The primary tumour, cervix, uterus, parametria and
pelvic lymph nodes (including the common iliacs) were deli-
neated on the planning CT scan.
The standard protocol for patients with Stage IIB to IIIB cervical
carcinoma is concurrent chemoradiotherapy. The regimen
includes 46–50 Gray (Gy) in 22–25 fractions of EBRT, four to six
cycles of weekly chemosensitisation with cisplatin (40 mg/m2)
in those without contra-indications, followed by high-dose-rate
(HDR) brachytherapy 20–25 Gy in four to five fractions. The
total equivalent dose in 2 Gy fractions to Point A was derived
for each patient.
External beam treatment was delivered using a linear accelera-
tor, with 6–18 MV energy beams equipped with a multi-leaf col-
limator. Treatment was given daily, five days a week. Standard
fraction size was 2 Gy, but alternate dosing of 1.8 Gy per fraction
was used in cases of HIV-positive patients or patients receiving
therapy to para-aortic nodes (PAN). In these cases the PAN
field received 45 Gy while the pelvic field received 50.4 Gy.
HDR brachytherapy was commenced in the fifth week of EBRT.
The dose was delivered by a Varian GammaMed® machine
(Varian Medical Systems Inc, Palo Alto, CA, USA) using a
192Iridium source.
In cases of renal impairment, poor performance status and
comorbidity (for example pulmonary tuberculosis) chemosensi-
tisation was not initiated.
Ethics
The study protocol was reviewed and approved by the Health
Research Ethics committee of the University of Stellenbosch.
Statistics
Demographic variables were evaluated using frequency stat-
istics. Univariate analysis was performed with chi-squared calcu-
lations. Overall survival was calculated by evaluating the time
from the end of treatment to the date of last follow-up or
death. Kaplan–Meier analysis was used to calculate the overall
survival rate from the date of completion of treatment to date
of death. Variables identified as significant or showing a trend
to significance by univariate analysis were subsequently ana-
lysed using the multivariate Cox proportional hazard model to
clarify the association between survival and the identified risk
factors; p < 0.05 was considered to indicate a statistically signifi-
cant difference. IBM SPSS® version 24 (IBM Corp, Armonk, NY,
USA) was used to analyse the data.
Results
Demographics
Of a total of 82 patients with locally advanced cervical carcinoma
who were identified during the study time period, a final cohort
of 71 patients remained when exclusion criteria were applied.
All patients received a dose of ≥ 66 Gy EQD2 of radiation. The
mean EQD2 received was 77.8 Gy (66.7 Gy–85.2 Gy). The
overall treatment time for those who completed treatment
was equal to or less than 58 days (36–58). Mean overall treat-
ment time was 45 days.
Of the 45 patients who began platinum-based chemotherapy,
40 (88.9%) completed four or more cycles. Chemotherapy was
not prescribed in 26 patients, due to poor renal function,
poor performance status, CD4 cell count < 200, active pul-
monary tuberculosis, or prescription of hypofractionated
radiotherapy.
The median age was 48.5 years (23–77 years); eight patients
(11%) were HIV-positive and seven (9.8%) patients had hydrone-
phrosis at time of staging. The cohort included 22 Stage IIB
patients (31%) and 49 Stage IIIB patients (69%). Table 1 shows
the clinical characteristics for the cohort.
The median PTV was 653 cc for the cohort. Stage IIB had a
median of 596.97 (iQR 499.87–775.31 cc) and for Stage IIIB the
median was 669.2 cc (iQR 509.54–835.81 cc). Large volumes
over 1000 cc were in most cases related to the presence of
hydrometria. PTV volume was not significantly influenced by
stage or HIV status, but a larger volume was significantly associ-
ated with suspicious enlarged lymph nodes on ultrasound
(Table 2).
Table 1: Clinical characteristics of the cohort
Cohort Number Percentage
n = 71 100%
Median age (years) 48.5 (23–77)
Age:
< 44 24 34%
44–56 23 32%
> 56 24 34%
Stage:
IIB 22 31%
IIIB 49 69%
Chemotherapy cycles:
≥ 4 cycles 40 56%
0–3 cycles 31 44%
HIV status:
Positive 8 11%
Negative 63 89%
Nodal status:
Positive/suspicious 12 17%
Negative 59 83%
Hydronephrosis
(Stage IIIB only):
Present 7 14.3%
Absent 42 85.7%
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Survival
At five years the overall survival for the entire cohort was 59%,
71.1% for Stage IIB patients and 53.1% for Stage IIIB. A planning
target volume less than 653 cc had a lower overall survival (OS)
of 47.4% compared with 69.3% for those with a larger PTV (p =
0.135) (Figure 1).
On univariate analysis the data demonstrated that factors signifi-
cantly associated with poorer overall survival were HIV status
and the presence of hydronephrosis.
A Cox regression model was constructed including age, stage,
hydronephrosis, nodal status, HIV status, tumour size and com-
pletion of four or more cycles of chemotherapy.
The data from the multivariate analysis demonstrated that the
factors which significantly impacted on overall survival in this
small cohort include HIV-positivity, Stage IIIB disease, the pres-
ence of hydronephrosis and paradoxically small planning
tumour volumes (Table 3).
Discussion
In this small cohort study of a subset of cervix carcinoma
patients who completed radical radiotherapy, a smaller planning
tumour volume was associated with lower overall survival.
Additional factors included HIV-positivity, Stage IIIB disease
and the presence of hydronephrosis.
Evidence suggests that tumour volume should be considered
when determining the prognosis in early cervical cancer.2–5 In
advanced cases, very few studies have been performed
looking at the effect of tumour volume on overall survival.
Tumour size has generally been determined by pelvic examin-
ation. This in itself can be problematic. Clinical examination is
not very reliable and understandably differs between observers.
The limitations to clinical staging are especially apparent in
advanced disease. A more precise and objective method, such
as CT or MRI, is preferable.7 Walsh et al. demonstrated that
even the use of CT is not entirely accurate in determining
tumour volume, as this modality does not provide adequate
evaluation of parametrial involvement. This is due to low soft
tissue contrast resolution. MRI on the other hand is an
imaging method that has several benefits, including improved
soft tissue contrast (leading to accurate tumour size measure-
ment and assessment of surrounding soft tissue invasion),
improved assessment of depth of stromal invasion and lymph
node evaluation.8 Due to resource limitations no advanced
stage patient was imaged with either CT or MRI in our institution
during the study period.
Evidence for the effect of tumour volume on overall survival
includes studies using many different imaging techniques and
methods of determining tumour size and its relation to
outcome. Soutter et al. investigated pre-treatment tumour
volume measurement on MRI as a predictor of survival in early
cervical cancer.9 Results suggest that the size of the tumour,
rather than the extent of the disease anatomically, determines
outcome. Tumour size > 4 cm as measured on MRI was also
found to be a poor prognostic factor by Toita et al. from
Japan.10 This finding was in contradiction to their earlier CT-
based work, which found that enlarged pelvic nodes was signifi-
cantly associated with poor outcomes, while tumour size had
limited prognostic value.11 Our small study demonstrates our
limitations of using CT-derived PTV alone as a surrogate for
tumour volume.
Lee et al. found that tumour volume > 33 ml and pelvic lymph
node involvement seen on MRI were related to an unfavour-
able outcome.12 Kyung et al. showed similar results on multi-
variate analysis for tumour sizes > 4 cm and involved
nodes.13 Limitations of MRI include lack of distinction
between metastatic and non-metastatic lymph node hyperpla-
sia as well as difficulty in determining exact tumour size.
Tumour is sometimes indistinguishable from normal tissue
and some centres use the entire cervical volume when com-
paring outcomes in patients. The use of a planning CT to delin-
eate tumour size is even more challenging and may have
contributed to our negative findings.
Figure 1: Kaplan-Meier graph comparing overall survival between two
tumour volume subgroups.
Table 3: Prognostic factors for overall survival
Variables Hazard ratio 95% CI p-value
Age > 50years 1.14 0.54–2.39 0.74
Stage IIIB 5.55 1.71–18.10 < 0.01*
Positive/suspicious nodes 0.65 0.19–2.31 0.51
Hydronephrosis 4.09 1.24–13.48 0.02*
HIV-positive 12.95 4.01–41.86 < 0.01*
PTV < 653 cc 2.77 1.14–6.72 0.02*
Chemo < 4 cycles 0.92 0.42–2.04 0.84
*p < 0.05 = significant.
Table 2: Correlation of clinical characteristics and PTV
Factor
PTV ≤
653
n (%)
PTV > 653
n (%)
All n
(%)
p-
value
HIV status:
Negative 32 (91.4%) 31 (86.1%) 63 (88.7%) 0.479
Positive 3 (8.6%) 5 (13.9%) 8 (11.3%)
Nodal status:
Negative 33 (94.3%) 26 (72.2%) 59 (83.1%) 0.013*
Positive/
suspicious
2 (5.7%) 10 (27.8%) 12 (16.9%)
Hydronephrosis (Stage IIIB):
No 20 (90.9%) 22 (81.5%) 42 (85.7%) 0.348
Yes 2 (28.6%) 5(18.5%) 7 (14.3%)
Stage:
Stage IIB 13 (37.1%) 9 (25%) 22 (31%) 0.269
Stage IIIB 22 (62.9%) 27 (75%) 49 (69.0%)
p < 0.05 = statistically significant
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Functional imaging including positron emission tomography
alone or combination PET/CT may assist in this regard. PET/CT
can be utilised in many ways—including in the initial evaluation
of the primary tumour, metastatic work-up and fusion with the
planning scan to assist with tumour/lymph node delineation in
radiotherapy planning. The functional information supplied by
PET/CT offers greater sensitivity and specificity when compared
with CT or other anatomic imaging methods.14 This method is
superior to conventional imaging for detecting metastases. In
a study by Grigsby et al., tumour volume and lymph node invol-
vement determined by PET/CT predicted overall survival.15 In
more recent years PET/CT has been increasingly performed in
our centre for Stage IIIB patients. This is done to detect possible
pelvic and para-aortic nodal involvement, metastatic disease
and to assist in tumour delineation. Future studies from this
institution will include PET/CT information in determining
outcomes.
Additional factors related to poor survival outcomes in this
cohort included HIV-positivity, advanced stage disease and
hydronephrosis. HIV status was considered a poor prognostic
factor by Simonds et al. in a retrospective trial performed at
this institute.16 This was thought to be partially due to
larger tumour volume and interruptions or cessation of treat-
ment in HIV-positive patients. In a prospective study per-
formed by Dryden-Peterson et al., analysis showed that HIV
infection significantly increased the risk for death among all
women with cervical cancer receiving concurrent
chemoradiation.17
International data on survival by stage include the Vale meta-
analysis, which indicated survival benefits in all stages of cervical
cancer when comparing radiotherapy alone with concomitant
chemoradiation.18 These effects were modest, but significant.
Estimated additional survival benefits were 7% in Stage IIB,
and 3% in Stage IIIB at five years. This was confirmed in a
meta-analysis from Dutta et al., which strictly assessed only
primary chemoradiation versus radiation alone in patients who
did not undergo surgery.19 OS benefit was in the order of
7.5%. It is noted the individual studies included in this meta-
analysis had small patient numbers but when pooled amount
to 2 245 study subjects. The five-year overall survival rates for
these stages are 65–75% (Stage IIB) and 35–50% (IIIB) with radio-
therapy alone. This corresponds with our observed survival rates
per stage (Stage IIB 64%; Stage IIIB 41%) for the HIV-negative
patients indicating outcomes comparable to many centres in
the developed world. It is noted that completion of chemother-
apy did not influence overall survival in our small cohort despite
over 40% of patients not completing four or more cycles of
chemotherapy.
The limitations of this study include the study design being
retrospective in nature and a small sample based at a
single institution. This could imply a poor statistical power
of all results. It is noted there are wide confidence intervals
in the statistically significant results. In addition, if the
effect of tumour volume on overall survival is to be studied,
a true representation of tumour volume should be obtained;
PTV (planning tumour volume) was used as a substitute for
this study. This vastly over-estimates tumour volume,
especially in cases where hydrometria was present. Five-
year progression-free survival or disease-free survival was
not evaluated due to the numbers lost to follow-up in our
clinical setting. Toxicities secondary to treatment were not
considered.
Strengths include a standardised treatment regimen for patients
and overall survival rates for chemoradiation in our institution
comparable to international studies. Tumour volumes were deli-
neated and planned by the same medical personnel, and there-
fore inter-observer variation was minimised.
Conclusion
The purpose of this small cohort study was to evaluate the utility
of planning target volume as a surrogate marker for survival out-
comes in a resource-limited setting.
It is our conclusion that, when using planning target volumes, our
hypothesis that larger volumes impact on overall survival was dis-
proved. HIV status and advanced tumour stage did impact on
outcome, consistent with international data. A larger cohort
and more accurate methods of determining tumour volume,
including PET/CT,will be considered in future prospective studies.
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